These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 5355632)

  • 21. [Use of ornithine carbamoyltransferase in the treatment of liver diseases].
    Caruso N; De Jacobis M; Roccato M; Sequino A; Sgoifo B; Tinello M
    Clin Ter; 1984 Jul; 110(1):37-44. PubMed ID: 6237844
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of ornithine alpha-ketoglutarate in clinical nutrition of elderly patients.
    Blonde-Cynober F; Aussel C; Cynober L
    Nutrition; 2003 Jan; 19(1):73-5. PubMed ID: 12507647
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical study on the effects of L-ornithine-L-aspartate on liver dysfunction].
    Kosozu K
    Iryo; 1966 Apr; 20(4):339-46. PubMed ID: 5974192
    [No Abstract]   [Full Text] [Related]  

  • 24. Ornithine alpha-ketoglutarate: the puzzle.
    Le Boucher J; Eureng ; Cynober LA
    Nutrition; 1998; 14(11-12):870-3. PubMed ID: 9834933
    [No Abstract]   [Full Text] [Related]  

  • 25. [Recent findings in drug treatment of liver disease patients with ornithine-carbamyl-transferase (OCT). Personal experience].
    Alvisi V; Tralli M; Tampieri ML; Lo Ponte A; D'Ambrosi A
    Minerva Dietol Gastroenterol; 1982; 28(4):335-40. PubMed ID: 7167246
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of alpha-difluoromethyl ornithine on the transplantable rat hepatoma 5123, 1-1.
    Kellen JA; Chan AW; Mirakian A
    Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):377-80. PubMed ID: 6777839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of ornithine alpha-ketoglutarate on the nutritional state of intensive-care patients].
    Demarcq JM; Delbar M; Trochu G; Crignon JJ
    Cah Anesthesiol; 1984 Mar; 32(3):229-32. PubMed ID: 6442191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does dietary ornithine alpha-ketoglutarate supplementation protect the liver against ischemia-reperfusion injury?
    Schuster H; Blanc MC; Genthon C; Thérond P; Bonnefont-Rousselot D; Le Tourneau A; De Bandt JP; Cynober L
    Clin Nutr; 2005 Jun; 24(3):375-84. PubMed ID: 15896423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
    Seki S
    Iryo; 1966 Apr; 20(4):354-63. PubMed ID: 5974194
    [No Abstract]   [Full Text] [Related]  

  • 30. [Digestive disorders casused by ethionamide treatment in children. Prevention by a combination with an ornithine base].
    Sarrouy C; Vaillaud JC; Sabatini R
    Pediatrie; 1965 Jun; 20(4):465-8. PubMed ID: 5843371
    [No Abstract]   [Full Text] [Related]  

  • 31. [Electroencephalographic study of the action of ornithine alphaketoglutarate in brain diseases caused by chronic alcoholic intoxication].
    Morice J
    Therapeutique; 1969; 45(6):635-8. PubMed ID: 5398587
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative clinical trial of karsil and legalon in patients with chronic liver lesions. III. Comparison of the effect of karsil and legalon on a 3-point system].
    Krŭstev Z; Ognianov M; Lukanov L; Ivanchev T; Mateva L
    Vutr Boles; 1984; 23(4):37-9. PubMed ID: 6390971
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical trial of liver-protective agents containing cytidine and uridine in the therapy of patients with liver diseases].
    Grimaldi N; Santoro C
    Policlinico Med; 1971; 78(3):134-46. PubMed ID: 5568445
    [No Abstract]   [Full Text] [Related]  

  • 34. Pretreatment of starved rats with ornithine alpha-ketoglutarate: effects on hepatic mRNA levels and plasma concentrations of three liver-secreted proteins.
    Segaud F; Lardeux B; Alexandre-Gouabau MC; Bleiberg-Daniel F; Nakib S; Cynober L; Moinard C
    Nutrition; 2005 Jun; 21(6):732-9. PubMed ID: 15925299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.
    Sjoerdsma A; Golden JA; Schechter PJ; Barlow JL; Santi DV
    Trans Assoc Am Physicians; 1984; 97():70-9. PubMed ID: 6442954
    [No Abstract]   [Full Text] [Related]  

  • 36. Alternative pathway therapy for hyperammonemia in liver failure.
    Larsen FS; Wendon J
    Hepatology; 2009 Jul; 50(1):3-5. PubMed ID: 19441099
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical trial of injectable ampicillin in hepato-biliary diseases in particular].
    Fraisse H; Etaix JP
    Lyon Med; 1966 Jan; 215(5):271-7. PubMed ID: 5909728
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical experiences with heparmez].
    Baumann M
    Z Allgemeinmed; 1970 Jun; 46(17):895-900. PubMed ID: 5509064
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical trial of the intravenous administration of a combination of amino acids and of an antitoxic liver extract].
    Malvicini G; Tinozzi S
    Minerva Med; 1968 Mar; 59(19):1027-33. PubMed ID: 5646216
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of ornithine on neutrophil (PMN) free amino acid and alpha-keto acid profiles and immune functions in vitro.
    Mühling J; Fuchs M; Campos M; Gonter J; Sablotzki A; Engel J; Welters ID; Wolff M; Matejec R; Dehne MG; Menges T; Krüll M; Hempelmann G
    Amino Acids; 2004 Dec; 27(3-4):313-9. PubMed ID: 15538644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.